Reversol Disease Interactions
There are 7 disease interactions with Reversol (edrophonium).
Cholinesterase inhibitor (applies to Reversol) bradycardia
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.
References
- Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988): 1305
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- Baldessarini RJ, Gelenberg AJ "Using physostigmine safely." Am J Psychiatry 136 (1979): 1608-9
- Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry 142 (1985): 738-40
- Dysken MW, Janowsky DS "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry 46 (1985): 446-7
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
- "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
Cholinesterase inhibitor (applies to Reversol) bronchospasm
Major Potential Hazard, High plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease, Asthma
Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment is recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.
References
- Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988): 1305
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
- "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
Cholinesterase inhibitor (applies to Reversol) coronary artery disease
Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease
The use of cholinesterase inhibitors has been associated with a constriction of coronary arteries. Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.
References
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
Cholinesterase inhibitor (applies to Reversol) parkinsonism
Major Potential Hazard, High plausibility.
Cholinesterase inhibitors should be used with caution in patients with parkinsonism. Some of these drugs might be contraindicated in these patients (refer to specific prescribing information). Symptoms of Parkinson's disease may be exacerbated with the increase in cholinergic activity. Caregivers and patients should be advised.
References
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- el-Yousef MK, Janowsky D, Davis JM, Sekerke HJ "Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study." Am J Psychiatry 130 (1973): 141-5
- Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
- "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
Cholinesterase inhibitor (applies to Reversol) PUD
Major Potential Hazard, High plausibility. Applicable conditions: Peptic Ulcer
The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.
References
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
- "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
Cholinesterase inhibitor (applies to Reversol) seizures
Major Potential Hazard, High plausibility.
Cholinesterase inhibitors have been associated with convulsions and tremor. Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.
References
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979): 283
- "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
- "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
- "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
Cholinesterase inhibitor (applies to Reversol) hyperthyroidism
Moderate Potential Hazard, High plausibility.
Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors. Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism. Monitoring of thyroid levels is recommended.
References
- "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
- Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255
- "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
- "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
- "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
Reversol drug interactions
There are 64 drug interactions with Reversol (edrophonium).
More about Reversol (edrophonium)
- Reversol consumer information
- Check interactions
- Compare alternatives
- Side effects
- Drug class: cholinergic muscle stimulants
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.